UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~April~~July 1122, 2008

~~EXPEDITION~~WEIKANG ~~LEASING~~BIO-TECHNOLOGY GROUP COMPANY, INC.

(Exact name of registrant as specified in Charter)

Florida _________________________	000-1365354 ____________________	20-1112910 _____________________________
Nevada _________________________	000-1365354 ____________________	26-2816569 _____________________________
(State or other jurisdiction of incorporation or organization)	(Commission File No.)	(IRS Employee Identification No.)

Economic & Technology Development Zone

Chengxu Village

Shuangcheng Town, Shuangcheng City

Heilongjiang Province, ~~PRC~~PR

(Address of Principal Executive Offices)

(86) 0451-88355530

(Registrant’s Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o [ ] Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

o [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~Forward Looking ~~4.01 Change in Registrant’s Certifying Accountant~~Statements

This Form 8-K and other reports filed by Registrant from time to time with the Securities and Exchange Commission (acollectively the “Filings”) ~~Dismissal~~contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, Registrant’s ~~Certifying~~management ~~Accountant~~as well as estimates and assumptions made by Registrant’s management. When used in the filings the words “anticipate”, “believe”, “estimate”, “expect”, “future”, “intend”, “plan” or the negative of these terms and similar expressions as they relate to Registrant or Registrant’s management identify forward looking statements. Such statements reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors (including the risks contained in the section of this current report entitled “Risk Factors”) relating to Registrant’s industry, Registrant’s operations and results of operations and any businesses that may be acquired by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

~~Effective~~Although ~~April~~Registrant 7,believes ~~2008~~that the expectations reflected in the forward looking statements are reasonable, ~~Pender~~Registrant ~~Newkirk &~~cannot ~~Company~~guarantee ~~LLP~~future ~~(“Pender~~results, ~~Newkirk”)~~levels ~~was~~of ~~dismissed~~activity, performance or achievements. Except as required by applicable law, including the ~~Company’s~~securities ~~certifying~~laws ~~independent~~of ~~accountant~~the ~~engaged~~United toStates, ~~audit~~Registrant does not intend ~~our~~to ~~financial~~update any of the forward-looking statements to conform these statements to actual results. ~~Pender~~The ~~Newkirk~~following ~~was~~discussion ~~engaged~~should asbe ~~auditors~~read toin ~~the~~conjunction with Registrant’s ~~for~~pro forma financial statements and the ~~year~~related ~~ended~~notes ~~December~~that ~~31,~~will ~~2006~~be filed herein.

~~Pender~~Item ~~Newkirk’s~~2.01 ~~report~~Completion onof ~~the~~Acquisition ~~Company’s financial statements for the two years ended December 31, 2006 did not contain any adverse opinions~~ or ~~disclaimers~~Disposition of ~~opinion,~~ ~~and were not qualified or modified as to uncertainty, audit scope, or accounting principles.~~Assets

~~Prior~~On July ~~to their~~22, ~~dismissal~~2008, ~~there~~Heilongjiang ~~were~~Weikang noBio-Technology ~~disagreements~~Group ~~with~~Co., ~~Pender~~Ltd. ~~Newkirk~~(“Heilongjiang Weikang”), onthe ~~any~~indirect ~~matter of~~wholly ~~accounting~~owned ~~principles~~subsidiary orof ~~practices~~Weikang Bio-Technology Group Co., ~~financial~~Inc. ~~statement~~(the ~~disclosure~~“Registrant”) orcompleted the acquisition (the “Acquisition”) of ~~auditing~~100% ~~scope~~of orthe ~~procedure,~~issued ~~which~~and ~~disagreements~~outstanding ifequity ~~not~~interests ~~resolved~~of toTianfang ~~the~~(Guizhou) ~~satisfaction~~Pharmaceutical ofCo., ~~Pender~~Ltd. ~~Newkirk~~(“Tianfang”), ~~would~~a ~~have~~Chinese ~~caused~~limited ~~them~~liability tocompany, ~~make~~for the ~~reference~~aggregate purchase price of $15,000,000 (the “Consideration”), pursuant to a ~~this subject~~Stock ~~matter~~Transfer ofAgreement (the ~~disagreements~~“Agreement”) indated ~~connection~~and ~~with~~entered ~~their~~into ~~report~~on June 30, 2008 ~~nor~~by ~~were~~and among the Heilongjiang Weikang, Tianfang, and Tianfang’s two ~~there~~shareholders, ~~any~~Beijing ~~"reportable~~Shiji ~~events"~~Qisheng asTrading ~~such~~Co., ~~term~~Ltd., asa ~~described~~Chinese inlimited liability ~~Item~~company ~~304~~(a“Shiji Qisheng”) and Tri-H Trade (1U.S.A.)~~(iv)~~ Co., Ltd., a ~~of Regulation~~California Scorporation (“Tri-BH”, and together with Shiji Qisheng collectively as the “Selling Shareholders”).

~~The~~Heilongjiang ~~Company~~Weikang ~~requested~~previously ~~Pender~~made ~~Newkirk~~a refundable deposit to ~~furnish~~Tianfang itin ~~with~~the ~~copy~~amount of $3,000,000 prior to the ~~letter~~for ~~addressed~~the purpose of accessing and examining the financial tobooks and records of Tianfang. At the ~~SEC~~closing ~~stating~~of ~~whether~~the itAcquisition, ~~agrees~~the ~~with~~entire amount of the ~~statements~~Deposit ~~made~~was ~~above~~applied bytoward the Consideration and paid to Tri-H ~~Company~~together ~~regarding~~with ~~Pender~~$810,000 ~~Newkirk.~~for ATri-H’s ~~copy~~pro rata ownership interests of Tianfang. Additionally, Heilongjiang Weikang issued a promissory note to Shiji Qisheng in the ~~letter~~amount byof ~~Pender~~$11,190,000 ~~Newkirk~~for Shiji Qisheng’s pro rata ownership interests of Tianfang. The promissory note is without interest, and is payable in two ~~attached~~installments, asthe ~~Exhibit~~first ~~16.1~~due to90 ~~this~~calendar ~~Form~~days ~~8-K~~from the date of the Agreement in the amount of $2,000,000, and the second due on the first anniversary of the Agreement date in the amount of $9,190,000.

~~(b)~~Other than ~~Appointment~~in ofrespect to the Acquisition, there is no material relationship between the Registrant’s, ~~New~~its ~~Certifying~~officers ~~Accountant~~and directors, and Tianfang and the Selling Shareholders.

Effective on April 7, 2008, Goldman Parks Kurland Mohidin-GPKM LLP (“GPKM”), whose address is 16133 Ventura Blvd., Suite 880, Encino, CA 91436, was engaged to serve as the Company's new independent certifying accountant to audit the Company's financial statements.

Prior to engaging GPKM, the Company had not consulted GPKM regarding the application of accounting principles to a specified transaction, completed or proposed, the type of audit opinion that might be rendered on the Company’s financial statements or a reportable event, nor did the Company consult with GPKM regarding any disagreements with its prior auditor on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of the prior auditor, would have caused it to make a reference to the subject matter of the disagreements in connection with its reports.

The dismissal of Pender Newkirk as the Company’s certifying independent accountant and the engagement of GPKM as its new certifying independent accountant were both approved by our Board of Directors.

Item 9.01 Financial Statements and Exhibits

(da) Financial ~~Exhibits~~Statement of Business Acquired. As permitted by Item 9.01(a) (4) of Form 8-K, the Registrant will file the financial statements required by Item 9.01(a) (1) of Form 8-K pursuant to an amendment to this current report on Form 8-K not later than seventy-one (71) calendar days after the date this current report must be filed.

Exhibit Number		Description
16.1		Letter from Pender Newkirk & Company LLP dated April 11, 2008.

(b) Pro-Forma Financial Information. As permitted by Item 9.01(b) (2) of Form 8-K, the Registrant will file the pro forma financial information required by Item 9.01 (b) (1) of Form 8-K pursuant to an amendment to this current report on Form 8-K no later than seventy-one (71) calendar days after the date this current report must be filed.

(d) Exhibits.

Exhibit Number		Description

2.1		Stock Transfer Agreement dated as of June 30, 2008 by and among Heilongjiang Weikang Bio-Technology Group Co., Ltd., Beijing Shiji Qisheng Trading Co., Ltd., Tri-H Trade (U.S.A.) Co., Ltd., and Tianfang (Guizhou) Pharmaceutical Co., Ltd.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 11, 2008	Expedition Leasing, Inc.
Date: July 23, 2008	Weikang Bio-Technology Group Co., Inc.
	By:	/s/ Yin Wang
		Yin Wang
		Chief Executive Officer

Filing Compare · WEIKANG BIO-TECH